Friday, 6 December 2013

Lupin launches Generic Trilipix® Delayed‐Release Capsules 45 mg & 135 mg  in the US 

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Fenofibric Acid Delayed‐Release Capsules 45 mg and 135 mg. 

Lupin had earlier received final approval from the US FDA for the same.  

Lupin’s Fenofibric Acid Delayed‐Release Capsules 45 mg and 135 mg are the generic equivalent of AbbVie Inc.’s Trilipix® Delayed‐Release  Capsules  45 mg &  135 mg strengths  are  indicated  as  co‐administration therapy  with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.  

Trilipix® Delayed‐Release Capsules 45 mg & 135 mg strengths had annual U.S sales of approximately US$ 449.5 million (IMS MAT Sep, 2013). 

No comments:

Post a Comment